Background Zatebradine is a bradycardic agent that inhibits the hyperpolarization-activated current (I f ) in the rabbit
The recording chamber contained a silver-silver chloride electrode connected to the CV-3 headstage of the Axopatch-1C voltage-clamp amplifier and Labmaster TL-1 DMA interface (Axon Instruments). The hKv1.5 current was measured by use of the whole-cell voltage-clamp configuration of the patch-clamp technique. 38 Micropipettes were pulled from borosilicate glass capillary tubes (Narishige, GD-1) on a P-87 programmable horizontal puller (Sutter Instrument) and heat polished with a microforge (Narishige). The micropipettes were filled with intracellular solution (see "Solutions") filtered through a micropore filter. Current records were sampled at 3 to 10 times the antialias filter setting and stored on the hard disk of a Hewlett Packard Vectra 486/33VL computer for subsequent analysis. Data acquisition and command potentials were controlled by use of PCLAMP 5.5.1. software (Axon Instruments). To ensure voltage-clamp quality, micropipette resistance was kept between 2 and 4 M . The microelectrodes were gently lowered onto the cells to obtain a gigaohm seal (16±6 G ; n=20) after suction was applied. After seal formation, cells were lifted from the bottom of the perfusion bath, and the membrane patch was ruptured with brief additional suction. The capacitive transients elicited by symmetrical 10-mV steps from -80 mV were digitized at 50 kHz (filtered at 10 to 20 kHz) for subsequent calculation of cell capacitance (21±2 pF; n=20) and uncompensated access resistance (7±2 M ; n=20). Thereafter, capacitance and series resistance compensation were optimized, and 80% compensation of the effective access resistance was usually obtained.
Solutions
The intracellular pipette-filling solution contained (in mmol/L) potassium-aspartate 80, KCl 50, KH 2 PO 4 
Pulse Protocol and Analysis
After control data were obtained, bath perfusion was switched to drug-containing solution. The holding potential was maintained at -80 mV. Drug infusion or removal was monitored with test pulses from -80 mV to +30 mV applied every 30 seconds until steady state was obtained (within 10 to 15 minutes). The cycle time for any protocol was 10 seconds to avoid accumulation of block or an incomplete reactivation of the current.
The protocol to obtain I-V relationships and activation curves consisted of 500-ms depolarizing pulses that were imposed in 10-mV increments between -80 and +60 mV with additional interpolated pulses to yield 5-mV increments between -30 and +10 mV (activation range of hKv1.5). 30 The steady-state I-V relationships were obtained by measuring the current at the end of the 500-ms depolarizations. Between -80 and -40 mV, only passive linear leak was observed, and least-squares fits to these data were used for passive leak correction. Deactivating tail currents were recorded on return to -30 mV. The activation curve was obtained from the tail current amplitude immediately after the capacitive transient. Measurements were made by use of the CLAMPFIT program of PCLAMP 5.5.1. and a custom-made analysis program. Activation curves were fitted with a Boltzmann equation
in which s represents the slope factor; E, the membrane potential; and E h , the voltage at which 50% of the channels are open. The time course of tail currents and the slow inactivation were fitted with the sum of exponentials. The activation kinetics were determined with the dominant time constant of activation approach, in which a single exponential was fitted to the latter 50% of activation. 30 39 40 The curve-fitting procedure used a nonlinear least-squares (Gauss-Newton) algorithm. Results were displayed in linear and semilogarithmic format together with the difference plot. Goodness of fit was judged by the 2 criterion and by inspection for systematic nonrandom trends in the difference plot. The same approach was used to fit the use-dependent onset of block and the recovery kinetics.
A first-order blocking scheme was used to describe drug-channel interaction. The apparent affinity constant, K D , and Hill coefficient, n H , were obtained from fitting of the fractional block, f, at various drug concentrations with the equation (E2) and apparent rate constants for binding (k) and unbinding (l) were obtained from fitting the equation
Voltage dependence of block was determined as follows: leak-corrected current in the presence of drug was normalized to matching control to yield fractional block at each voltage (f=1-I drug /I control ). The voltage dependence of block was fitted with the equation (E4) where z, F, R, and T represent valence, Faraday's constant, gas constant, and absolute temperature, respectively. The value represents the fractional electrical distance, ie, the fraction of the transmembrane electrical field sensed by a single charge at the receptor site, and K D * represents the apparent K D at the reference membrane potential (0 mV).
Statistical Methods
Results are expressed as mean±SEM. Direct comparisons between mean values in control conditions versus mean values in the presence of drug for a single variable were performed by use of a paired Student's t test. ANOVA was used to compare more than two groups. A value of P<.05 was considered significant.
Results
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Dose-Dependent and Reversible Block by Zatebradine
The top panel of Fig 1 shows superimposed original records of hKv1.5 in expressed Ltk -cells after the application of 500-ms depolarizing pulses from a holding potential of -80 mV to different test potentials between -40 and +60 mV. Under control conditions, the outward K + current rose rapidly with a sigmoidal time course to a peak and then declined slowly (slow and partial inactivation). The activation time constant was 0.90±0.13 ms at +60 mV (n=6). Outward tail currents were observed on repolarization to -30 mV that exhibited a time constant of deactivation of 53±13 ms. These results are similar to previous reports 30 31 41 of functional properties of hKv1.5 expressed in L cells. The bottom panel of Fig 1 shows that zatebradine 10 µmol/L did not modify the activation time constant (1.05±0.14 ms at +60 mV; n=5; P>.05). However, it reduced the peak outward potassium current modestly and induced a prominent decline that reached steady-state values at the end of a 500-ms pulse. This decline occurred much more quickly and to a greater extent than the slow inactivation observed in control conditions and therefore could be well separated from the intrinsic slow and partial inactivation observed under control conditions. Furthermore, a similar percentage of block was observed after 1-second duration pulses. When hKv1.5 block was measured at the end of a 500-ms pulse from -80 to +60 mV, zatebradine 10 µmol/L reduced the hKv1.5 current by 82±3% (n=7). After perfusion was switched with zatebradine, induction of block progressed with a time constant of 3 to 4 minutes, which was about five times slower than the effect of changing extracellular K + concentration at similar flow rates. This suggested an intramembrane or intracellular site of action, and therefore 15 minutes of equilibration was allowed to elapse before drug effects were assessed. The effects were reversible on washout of the drug. In 20 cells, the current was restored to 88±2% of its initial control value after perfusion with drug-free solution over a 20-minute period.
View larger version (19K):
[in this window] [in a new window] Fig 2 shows the concentration dependence of zatebradine-induced block of hKv1.5 measured at the end of 500-ms depolarizing pulses from -80 to +60 mV. In the presence of zatebradine, block averaged 21±5% (n=5) at 0. Fig 3A shows the effects of 2 µmol/L zatebradine on the steady-state I-V relationship for the hKv1.5 channel. Cells were held at -80 mV, and 500-ms depolarizing pulses were applied in steps of 10 mV to different potentials from -80 mV to +60 mV, with the exception of membrane potentials between -30 and +10 mV, in which depolarizing pulses were applied in 5-mV steps because this voltage range corresponds to the slope of the activation curve of the current. The I-V relationship under control conditions was almost linear for depolarizations positive to +10 mV, and the sigmoidicity between -30 and +10 mV reflects the voltage dependence of channel gating. 30 31 In the presence of zatebradine 2 µmol/ L, the curve displayed a downward curvature at test potentials positive to 0 mV, which suggested that this drug produced more block at very positive depolarizations. To quantify this voltage dependence of hKv1.5 block, the relative current I zatebradine /I control was plotted as a function of membrane potential ( Fig 3B ) together with the activation curve. The hKv1.5 block increased steeply between -30 and 0 mV, which corresponds to the voltage range of channel opening. These data suggest that zatebradine preferentially binds to the open state of the channel. Between 0 and +60 mV, block continued to increase with a more shallow voltage dependence, although hKv1.5 activation had reached saturation over this voltage range (Fig 3B ) . For instance, with zatebradine 2 µmol/L, the degree of block increased in a voltage-dependent manner from 43.7±3.4% at 0 mV to 52.9±3.3% at +60 mV (n=6). Paired analysis in six experiments with zatebradine 2 µmol/L indicated that this voltage-dependent increase in block was significant (difference, 9.1±1.5%; P<.01). Zatebradine is a weak base and has a tertiary amine group with pK a =8.73, 42 and thus, this drug will be predominantly present (99.5%) in its cationic form at the intracellular pH of 7.25. Therefore, the shallow voltage dependence of block at potentials positive to 0 mV could be due to the effect of the transmembrane electrical field on the interaction between the zatebradine ion and the channel receptor. 30 41 If zatebradine reaches the receptor from the inside, then channel block is expected to increase in a voltage-dependent manner according to a Boltzmann relationship (Equation 4 in "Methods"). The parameter in this equation represents the fractional electrical distance, ie, the fraction of the membrane electrical field sensed by a single charge at the receptor site. Fig 3B shows the fit of this equation to data points positive to 0 mV, with a of 0.18 for this particular experiment. In six experiments with zatebradine 2 µmol/L, the average value for was 0.177±0.002.
Voltage-Dependent Block by Zatebradine of hKv1.5 Channels
View larger version (16K):
[in this window] [in a new window] Figure 3 . Voltage dependence of hKv1.5 block by zatebradine (2 µmol/L). A, Current-voltage relationship (500 ms isochronal) in control and in the presence of zatebradine 2 µmol/L. B, Relative current expressed as I zatebradine /I control from data shown in Fig 3A. The dashed line represents the activation curve for this experiment. Block increased steeply between -20 and 0 mV ( ), which corresponds to the voltage range of activation of hKv1.5. For membrane potentials positive to 0 mV, a continued but more shallow voltage dependence was observed ( ). This voltage dependence was fitted (continuous line) with use of Equation 4 (see "Methods") and yielded =0.18.
Concentration Dependence of Time Course of Channel Block
If zatebradine can access its receptor site only when the hKv1.5 channel is opened, then the inhibition of the potassium current would develop only when the channels start to open, and development of block should be visible during a 500-ms depolarizing step if the blocking rate is slower than the opening rate. On the other hand, if the blocking rate exceeded that of channel opening or if zatebradine blocked other states of the channel, the current recorded in the presence of drug would be expected to be scaled down. Fig 4 shows superimposed recordings of 500-ms depolarizations from -80 to +60 mV in the absence and presence of zatebradine 2 and 10 µmol/L. Under control conditions, the potassium current reached its maximum peak within 10 ms and then declined slowly, with a time constant of 160 ms (partial slow inactivation). However, in the presence of zatebradine, the subsequent time course displayed an additional exponential component superimposed on the slow inactivation that can be separated from the slow inactivation at concentrations 10 µmol/L. The decline of the current in the presence of zatebradine 2 µmol/ L was very slow; thus, the kinetics of development of block at this concentration was assessed by use of a double-pulse protocol in which a conditioning pulse of variable duration (from 10 to 5000 ms) to +60 mV was followed by a test pulse of 30 ms to +60 mV. This pulse protocol allowed us to separate the slow inactivation from the development of block in the presence of this low concentration of zatebradine. The current values measured at the end of the test pulse were plotted versus the time of the conditioning pulse and fitted by a monoexponential function that yielded a time constant of block of 434.5±18.0 ms (n=9). The time constants of the fast component in the presence of zatebradine 10 and 20 µmol/L were 109.2±16.3 (n=7) and 52.5±9.7 ms (n=7), respectively. These time constants ( B ), together with that obtained with the doublepulse protocol for zatebradine 2 µmol/L, can be taken as an approximation of the drug-channel interaction kinetics. 30 
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Use-Dependent Block of hKv1.5 Channels by Zatebradine
Although zatebradine 2 µmol/L induced over 50% steady-state block, this amount of block may not be attained during a single action potential. Therefore, we tested whether zatebradine-induced block displayed use dependence. Trains of 15 depolarizing pulses of 125-ms duration from -80 mV to +50 mV were applied at two different stimulation frequencies, 0.5 and 1 Hz. Fig 6 shows original current records obtained after such pulse train was applied at a frequency of 1 Hz in the absence and presence of zatebradine 10 µmol/L. Under control conditions, the outward K + current displayed little decline. In the presence of zatebradine 10 µmol/L, the size of the current decayed progressively until it reached a steadystate block after approximately 4 depolarizing pulses. Fig 6 also shows the effects of these pulse trains on the maximal peak currents elicited during the application of these pulse protocols in the absence and presence of zatebradine 10 µmol/L. Under control conditions, the maximal peak current decayed by 9±2% (n=4) and 10±3% (n=4) after application of trains of depolarizing pulses from -80 mV to +50 mV at 0.5 and 1.0 Hz, respectively. In the presence of zatebradine 10 µmol/L, there was a statistically significant use-dependent block at both frequencies of stimulation that averaged 30±3% (P<.01; n=4) and 44±3% (P<.01; n=4) at 0.5 Hz and 1.0 Hz, respectively. The analysis of this exponential decay yielded rate constants of 1.5±0.1 (n=4) and 1.0±0.3 pulse -1 (n=4) at 0.5 and 1.0 Hz, respectively. This use-dependent inhibition of hKv1.5 current was concentration dependent. Therefore, after application of a train of 15 depolarizing pulses from -80 mV to +50 mV at a frequency of 1 Hz in the presence of 2 µmol/L zatebradine, a 20±2% inhibition of the current was observed (n=4; P<.01). When the current inhibition was measured at the end of the 125-ms depolarizing pulses at 0.5 and 1 Hz in the absence and presence of zatebradine 10 µmol/L, the values obtained were 9±2% versus 35±4% (P<.01; n=4) and 9±3% versus 42±5% (P<.01; n=4), respectively.
View larger version (26K):
[in this window] [in a new window] These results indicated that block of hKv1.5 channels by zatebradine increased as the frequency of stimulation was augmented and could be explained if the recovery process of blocked channels (OZ O C) was slower than the transition between the open (O) and the closed (C) state in the absence of drug (Z). To explore this possibility, we determined the kinetics of the recovery process using the following experimental protocol: a conditioning prepulse of 500-ms duration from -80 to +60 mV was followed by a fixed test pulse of 500-ms duration to +50 mV after an interstimulus interval of variable duration (between 50 and 8000 ms) at -80 mV. trains of depolarizing pulses, since after interstimulus intervals of 1 and 2 seconds, there was still an accumulated percentage block of 45±2% and 27±2%, respectively.
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Mathematical Modeling
The experimental results obtained in the present study were interpreted and simulated by use of a kinetic-state diagram similar to those used for the related Drosophila Shaker and rat brain RCK1 (Kv1.1) voltage-gated potassium channels 43 and that was previously described for this hKv1.5 channel. 31 41 A simple way to incorporate the interaction of zatebradine into this diagram is to assume that the drug binds to the open state of the channel, as indicated in the scheme. Since the activation process is fast, at potentials positive to 0 mV, this system functionally reduces to a three-pool model (I O OZ). In the presence of zatebradine, the inactivation became biexponential, as expected for this model. The drug-induced extra component of inactivation had a time constant that was much faster than that of the slow inactivation of the current under control conditions. Therefore, this fast time constant The open-channel block model was used with the following rate constants: at +60 mV, =400 s -1 , ß=1 s -1 , k=1.1 (µmol/L) -1 ·s -1 , and l=1.6 s -1 ; at -30 mV, =0.1 s -1 , ß=7 s -1 , k=0.7 (µmol/L) -1 ·s -1 , and l=2.6 s -1 . A, Mathematical simulations for maximal outward currents elicited during 250-ms steps from -80 to +60 mV. B, Mathematical simulations for tail currents elicited during a 250-ms step to -30 mV applied after a 250-ms step to +60 mV. Arrow indicates tail current crossover. Currents for step and tail were scaled to reflect the difference in driving force.
Discussion
The main findings of the present study were as follows: (1) the charged form of zatebradine bound to the open state of hKv1.5 channels; (2) binding occurred within the transmembrane electrical field and was described by a fractional electrical distance ( ) of 0.18; (3) zatebradine-induced block was use dependent; (4) the use-dependent block was due to a slow
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Abstract Introduction Methods Results Discussion References recovery from block in the presence of drug; and (5) unbinding was required before the channel could close. The K D for hKv1.5 block is only fourfold higher than that for use-dependent I f inhibition in rabbit sinoatrial node cells, 15 which suggests that this class III action may have clinical relevance.
Zatebradine Binds to the Open State of the hKv1.5 Channel
The block of hKv1.5 channels induced by zatebradine displayed time-, state-, and voltage-dependent interactions. In the presence of this drug, (1) there were no changes in the activation kinetics, (2) the block developed after channels opened and increased steeply in the voltage range of channel opening, and (3) a "crossover" phenomenon in the tail currents was observed. All these data strongly suggested an interaction of zatebradine with the open state of the hKv1.5 channel. The assumption that the fast component represented the O OZ transition did not apply at low drug concentrations, because the time constant of block was similar to that of slow inactivation. Therefore, we needed to use a double-pulse protocol to extract the kinetic information. The apparent binding and unbinding rate constants for zatebradine were calculated to be k=(1.14±0.27)x10 6 (mol/L) -1 ·s -1 and l=(1.63±3.55) s -1 . From these rate constants, the apparent affinity (K D =l/ k) was estimated to be 1.4 µmol/L. This estimate is in good agreement with the value obtained from steady-state suppression of the hKv1.5 current (1.86 µmol/L). This agreement between both independent methods to estimate the affinity further supports the open-channel block model used to derive the rate constants.
Voltage Dependence of Zatebradine Block
Zatebradine is a weak base, with a pK a of 8.73 42 ; therefore, 99.5% of the drug is in its charged form at pH 7.4, and 0.5% is in its neutral form.
Access of the hydrophilic (charged) form of the drug to the receptor site requires a hydrophilic pathway. 42 44 This mode of access most likely requires that the charged drug move into the electrical membrane field. This provides an additional attraction to or repulsion from the receptor. Depolarization will promote the entry of a cationic drug from the inside into the channel, whereas hyperpolarization will decrease it. This interaction can be considered to change the drug concentration at the receptor site in a voltage-dependent manner or to modify the receptor affinity because it adds a voltage-dependent term to the rate constants of drug binding and unbinding. If a drug has a high affinity for activated and/or open channels, the voltage dependence of channel activation is superimposed on the intrinsic voltage dependence of drug binding because channel activation makes the receptor available. The total voltage dependence of block is then composed of a steep phase that reflects channel activation and a shallower phase that reflects the additional effect of the electrical field on the charged drug (see Fig 3B ) . Therefore, the value of 0.18 observed in the presence of zatebradine for the voltage dependence of the apparent K D can be interpreted to indicate that the positively charged zatebradine senses 18% of the membrane electrical field. It is of interest to note that the time constant of recovery from block at -80 mV was 1.5 seconds, ie, similar to the dissociation rate constant (l) obtained at +60 mV ( re =0.6 seconds from l=1.6 s -1 ). This indicates that the rate of dissociation displays no significant voltage dependence. This suggests that the drug is not trapped in the channel on hyperpolarization, because in that case we would expect much different values between potentials where the channel is open (+60 mV) or closed (-80 mV), and that the voltage dependence of block likely resides in the association rate constant (k) and not in the dissociation rate constant (l), which only decreases 2.6-fold, from -80 mV to +60 mV.
Receptor Site for Zatebradine on hKv1. 5 The voltage dependence observed in the presence of zatebradine strongly suggests that the binding site is located within the membrane electrical field. In other words, the receptor site for zatebradine is located in the membrane spannings of the hKv1.5 channel. The amino acid sequence 462 to 480 of hKv1.5 is identical to this "pore" sequence of the related Drosophila Shaker potassium channel, with the exception of the last amino acid (arginine in hKv1.5, threonine in Shaker). 29 Mutations on either end of the ion pore in Shaker alter the affinity for TEA (T441S for internal and T449Y for external TEA). 45 Internal TEA blocks Shaker K + channels with a voltage dependence described by an electrical distance of 0.15, 45 which suggests that TEA moves approximately 15% into the membrane electrical field. This value is similar to those previously described for quinidine ( =0.18), 31 R(+)-and S(-)-bupivacaine ( =0.16), 41 two enantiomers of a new benzazepin-2-on derivative with specific bradycardic effects ( =0.19), 46 and quinine ( =0.18) 36 and for zatebradine in the present experiments ( =0.18). All these findings may suggest the existence of a common receptor site for TEA, local anesthetics, and antiarrhythmic drugs both in Shaker and hKv1.5 channels. Moreover, the functional similarity between zatebradine-induced hKv1.5 block and that induced by TEA on Shaker channels, as well as the high structural similarity of the ion pores, would suggest that the T477 residue (equivalent of T441 Shaker) in hKv1.5 channels may be involved in zatebradine block. However, since zatebradine is a very hydrophobic molecule (logP=2.01), 42 we cannot rule out the possibility that other hydrophobic amino acids located in the pore of the channel also might be involved in the binding of zatebradine to hKv1.5 channels. Indeed, the residue at position 469 (Shaker B) within the S6 domain appears to contribute to the hydrophobic binding pocket for alkyl-TEA derivatives. 47 Variation of the hydrophobicity of this position by amino acid substitutions modulates the binding energy of the longer quaternary ammonium ions in a manner consistent with a direct hydrophobic interaction between the side chain of this residue and the alkyl tails of the blocker. Thus, the binding of zatebradine to the hKv1.5 channel pore could be similar to that of different alkyl-TEA compounds. Further studies with point mutations will help to test this hypothesis.
Clinical Implications
In isolated sinoatrial nodal cells, low concentrations of zatebradine (0.1 to 2 µmol/L) reduced the diastolic depolarization rate and blocked the I f in a use-dependent manner with an EC 50 value of 0.5 µmol/L without causing a shift of its activation curve. 15 However, in spontaneously beating sinoatrial nodal cells, rabbit Purkinje fibers, and guinea pig papillary muscles, zatebradine (1 µmol/L) also prolongs the action potential http://circ.ahajournals.org/cgi/content/full/94/3/562 (9 de 16)04/05/2010 11:58:42 duration. 15 19 20 These results suggest that zatebradine exhibits additional class III effects and that the prolongation of the ventricular action potential duration must be due to the inhibition of an outward K + current different from the I Kr present in rabbit sinoatrial myocytes.
In the present study, we have demonstrated that zatebradine blocks hKv1.5 channels in a concentration-, voltage-, time-, and use-dependent manner. Therefore, this effect on hKv1.5 channels could be the underlying mechanism by which zatebradine is able to prolong the action potential duration in sinoatrial node cells, papillary muscles, and Purkinje fibers. 15 19 20 In the present experiments, the steady-state K D value to block hKv1.5 channels was 1.8 µmol/L, which is less than four times higher than the value (0.5 µmol/L) for use-dependent inhibition of I f in sinoatrial node cells. 15 Moreover, we have also demonstrated that zatebradine-induced block of hKv1.5 channels was use dependent in such a way that at 0.5 and 1 Hz, zatebradine (10 µmol/L) inhibited the maximal peak hKv1.5 current by 40%, and this block persisted after 125-ms depolarizing pulses. Thus, it is possible that the reported steady-state K D underestimates the potency of zatebradine to block hKv1.5 channels.
Indeed, a recovery time constant of 1.5 seconds predicts that 60% of steady-state block will be maintained at 1 Hz. Thus, a concentration as low as 0.5 µmol/L would yield a 13% inhibition of the current by itself. The clinical relevance of the use-and frequency-dependent hKv1.5 block produced by zatebradine is currently unknown. The peak plasma levels found in healthy volunteers after intravenous and oral administration of zatebradine were 162±71 ng/mL and between 24 and 35 ng/mL, respectively. 13 14 Since zatebradine decreases I f and heart rate in a use-dependent manner, it would be expected that the frequency-dependent block of hKv1.5 channels was progressively relieved as the heart rate was slowed. However, these pharmacokinetic studies were performed in healthy volunteers after the administration of zatebradine at doses different from those recommended in patients with coronary heart disease (2.5 to 7.5 mg twice a day). 12 Furthermore, the terminal half-life after oral administration was 2 to 3 hours, whereas the anginal and bradycardic effects of zatebradine persisted for >10 hours. 12 Because of the discrepancy between pharmacokinetic data and clinical efficacy, it was suggested that the tissular concentration rather than the plasma level of zatebradine is relevant. 13 Under this assumption, the zatebradine-induced, use-dependent block of hKv1.5 channels could become of clinical relevance, since even at heart rates slower than the normal sinus rhythm (0.5 Hz), zatebradine is able to inhibit the hKv1.5-like current and thus prolong the action potential duration, probably with a K D value similar to that necessary to inhibit the I f in a use-dependent manner.
Moreover, the role of I f in pacemaking is still controversial, and other factors, including activation of L-and T-type Ca 2+ currents, the deactivation of delayed rectifier currents, a background Na + -dependent current, and the exchanger Na + -Ca 2+ background current, also are expected to play an important role in pacemaker activity. 48 49 50 51 Because the exact localization of hKv1.5 channels in the different regions of the heart is not known at the present time, we cannot rule out a potential role of these channels in modulation of pacemaker activity. 
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